Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)
(2) Inflammatory reprogramming via mesoporous silica nanoparticles loaded with anti-inflammatory miR-21, which target circulating platelet-monocyte aggregates post-MI/Rmembrane fusion enables direct monocyte delivery, reprogramming inflammatory macrophages toward reparative phenotypes [108]
101 , 15651573.e18 (2014)
These symptoms are typically transient but may lead to treatment discontinuation in approximately 5%10% of patients
A., Harish, Varjani, S., Singh, G., Marchand, J., Schoefs, B., & Vinayak, V
&srotate=0)
